Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
10/25/26 Akeso (9926) Idafang for Biliary Tract Cancer Subscribers Only Subscribers Only Subscribers Only
10/25/26 Roche (RO) divarasib for Non-Small Cell Lung Cancer (NSCLC) Subscribers Only Subscribers Only Subscribers Only
10/25/26 AstraZeneca (AZN) sonesitatug vedotin for Esophageal Cancer Subscribers Only Subscribers Only Subscribers Only
10/25/26 AstraZeneca (AZN) sonesitatug vedotin for Gastric Cancer Subscribers Only Subscribers Only Subscribers Only
10/24/26 Daiichi Sankyo (4568) Enhertu for Non-Small Cell Lung Cancer (NSCLC) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
07/31/2025 Subscribers Only Subscribers Only Regulatory - sNDA/sBLA Filing
07/31/2025 Subscribers Only Subscribers Only Regulatory - IND/CTA Filing
10/28/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
10/31/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
11/11/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update